SK Biopharmaceuticals Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	307,771	322,807	239,700	104,060	225,922
Short-Term Investments	1,711	1,682	1,418	201,394	108,417
Cash & Short-Term Investments	309,482	324,489	241,118	305,454	334,339
Cash Growth	-4.63%	34.58%	-21.06%	-8.64%	-13.83%
Accounts Receivable	228,826	173,819	111,001	63,506	55,883
Other Receivables	450.84	433.79	2,641	2,945	1,477
Receivables	229,276	174,253	113,642	66,451	57,360
Inventory	100,240	111,679	102,525	90,920	51,933
Prepaid Expenses	28,905	30,125	25,898	18,734	20,964
Other Current Assets	15,326	10,825	5,538	6,366	6,622
Total Current Assets	683,229	651,371	488,722	487,925	471,219
Property, Plant & Equipment	60,510	43,932	47,753	20,350	22,938
Long-Term Investments	66,002	91,439	104,091	99,959	107,665
Goodwill	1,650	1,691	3,392	-	-
Other Intangible Assets	5,338	8,875	14,542	17,181	18,900
Long-Term Deferred Tax Assets	325,775	206,400	44,723	29,641	18,919
Long-Term Deferred Charges	44,227	21,963	9,090	-	-
Other Long-Term Assets	11,526	11,059	10,771	9,107	3,985
Total Assets	1,198,309	1,036,811	723,171	664,241	643,652
Accounts Payable	9,337	3,403	2,346	23,106	16,931
Accrued Expenses	94,637	79,653	71,331	55,035	64,776
Short-Term Debt	-	-	50,000	-	-
Current Portion of Long-Term Debt	-	150,715	-0	-	-
Current Portion of Leases	8,429	7,091	7,061	5,644	5,481
Current Income Taxes Payable	2,100	451.82	88.78	208.36	1,997
Other Current Liabilities	180,697	154,962	110,792	79,079	59,120
Total Current Liabilities	295,200	396,276	241,619	163,073	148,306
Long-Term Debt	-	-	94,484	143,722	-
Long-Term Leases	40,491	26,676	26,505	6,530	10,256
Pension & Post-Retirement Benefits	-	-	-	-	52.72
Long-Term Deferred Tax Liabilities	-	-	1,909	-	-
Other Long-Term Liabilities	36,349	39,874	37,703	34,356	40,850
Total Liabilities	372,039	462,827	402,219	347,681	199,465
Common Stock	39,157	39,157	39,157	39,157	39,157
Additional Paid-In Capital	1,084,848	1,084,848	1,084,848	1,084,848	1,084,848
Retained Earnings	-354,142	-621,532	-861,561	-827,555	-689,141
Comprehensive Income & Other	43,173	43,800	21,243	20,112	9,325
Total Common Equity	813,036	546,273	283,686	316,560	444,187
Minority Interest	13,234	27,711	37,265	-	-
Shareholders' Equity	826,270	573,984	320,951	316,560	444,187
Total Liabilities & Equity	1,198,309	1,036,811	723,171	664,241	643,652
Total Debt	48,920	184,482	178,050	155,896	15,738
Net Cash (Debt)	260,562	140,007	63,068	149,558	318,602
Net Cash Growth	86.11%	121.99%	-57.83%	-53.06%	-13.78%
Net Cash Per Share	3327.18	1787.78	805.33	1909.74	4068.30
Filing Date Shares Outstanding	78.31	78.31	78.31	78.31	78.31
Total Common Shares Outstanding	78.31	78.31	78.31	78.31	78.31
Working Capital	388,029	255,095	247,104	324,852	322,914
Book Value Per Share	10381.84	6975.49	3622.46	4042.23	5671.93
Tangible Book Value	806,048	535,708	265,752	299,380	425,288
Tangible Book Value Per Share	10292.61	6840.58	3393.45	3822.85	5430.60
Machinery	32,819	32,717	30,611	21,078	19,165
Construction In Progress	4,591	201.95	236.84	1,643	1,276

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.